People vaccinated for Covid have increased risk of neurological diseases – study

The study was part of the GVDN’s Global COVID Vaccine Safety Project and was funded entirely by a $10 million grant from the US Centers for Disease Control and Prevention (CDC).

Data from almost 100 million people compares the expected and observed incidents of side effects

A big data study of 99 million people across eight countries showed greater than expected incidence of side effects from various Covid-19 vaccines, the Global Vaccine Data Network (GVDN) said on Monday.

The study*{link at the bottom], originally published in the medical journal Vaccine on February 12, 2024, looked at 13 neurological, blood, and heart-related conditions, called “adverse events of special interest.” Researchers looked at 99,068,901 vaccinated individuals from ten sites in eight countries.

“The size of the population in this study increased the possibility of identifying rare potential vaccine safety signals,” said Kristyna Faksova, the lead author of the study from the Statens Serum Institut in Copenhagen, Denmark.

According to the GVDN, the study observed a greater incidence of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart sac) than expected among those who took the Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) shots.

Moderna’s vaccine also had a higher rate of acute disseminated encephalomyelitis (ADEM, inflammation and swelling in the brain and spinal cord), with seven observed events compared to two expected within 42 days of the first shot.

Safety signals for myocarditis were “consistently identified” following the first three doses of either mRNA shot, with the highest ratio after the second dose. Signals for pericarditis also appeared following the first and fourth doses of mRNA-1273 and were also observed after a third dose of the Oxford/Astra Zeneca (ChAdOx1) viral vector vaccine.

Recipients of ChAdOx1 had 190 observed events of Guillain-Barré Syndrome (GBS) compared to the expected 76, and 69 observed instances of cerebral venous sinus thrombosis (CVST, a type of blood clot in the brain) compared to the expected 21, the study has shown.

The GVDN has made the results available to the public on its interactive data dashboards, along with a warning not to read too much into correlations and that the vaccines are both safe and effective.

“By making the data dashboards publicly available, we are able to support greater transparency, and stronger communications to the health sector and public,” GVDN co-director Dr. Helen Petousis-Harris said.


Post deleted by user…

And they only looked at adverse events of special interest for 42 days, not other side effects and not even at mortality

1 Like

Recipients of ChAdOx1 had 190 observed events of Guillain-Barré Syndrome (GBS) compared to the expected 76, and 69 observed instances of cerebral venous sinus thrombosis (CVST, a type of blood clot in the brain) compared to the expected 21, the study has shown.

I wonder how high the incidence of it would’ve been in a saline shot placebo group…

1 Like

A new study from Israel ties COVID-19 infection to an increased risk of a diagnosis of Guillain-Barre syndrome (GBS) within 6 weeks, while mRNA vaccination was linked to a decreased risk of the rare but serious autoimmune disease.

The study was published today in Neurology.

Researchers from Lady Davis Carmel Medical Center in Haifa conducted a nested case-control study involving 3,193,951 patients aged 16 years and older not previously diagnosed as having GBS seen at Clalit Health Services from January 2021 to June 2022. Each patient with GBS in the 6 weeks after infection was matched with 10 randomly selected control patients who did not have GBS.

A chronic illness with no known cure, GBS occurs when the immune system attacks the nerves, causing symptoms such as weakness and tingling in the hands and feet that spreads to the upper body and may lead to paralysis, shortness of breath, abnormal blood pressure, and difficulty walking. Most people recover with few residual effects.

Odds of GBS after vaccination only 0.41

Two thirds of GBS patients reported that they had symptoms of a respiratory or gastrointestinal infection in the 6 weeks before GBS diagnosis. A total of 76 patients were diagnosed as having GBS during follow-up and were matched with 760 control patients. The average age of GBS patients was 56.3 years, and half were women.

Nine of the 76 GBS patients (11.8%) and 18 of 760 controls (2.4%) had tested positive for COVID-19. Eight (10.5%) of GBS patients and 136 (17.9%) controls had been vaccinated against COVID-19, nearly all of them with the Pfizer/BioNTech vaccine.


“Long COVID includes a wide range of ongoing respiratory, neurologic, cardiovascular, and other symptoms that can last for weeks, months, or years following SARS-CoV-2 infection. Estimates of long COVID incidence among nonhospitalized adults with COVID-19 range from 7.5% to 41%."1


Just for the record I’m not a huge fan of the quick rollout and widespread vaccination with COVID-19 mRNA vaccine. I think beyond maybe the initial 2 dose regimen of delta variant, the booster shots should have been recommended for selective population. For one mRNA vaccine create massive inflammatory response and cytotoxic reactions, since the spike proteins are presented on the cells. This makes an effective vaccine but also potentially can lead to more side effects.
The huge elephant in the room was vaccinating people that were already infected with COVID-19 and developed immunity - especially mucosal IgA. It’s very possible that those people could have stopped the virus right at the mucosal level. So giving them a booster would result in skewed benefit to risk ration, leaning towards risk.
Anyway, just bunch of opinions here.


I don’t see this study mentioning whether the people who got myocarditis from a covid19 infection were vaccinated. All that should matter is whether the people with myocarditis got the covid vaccine, period.

The point of contact for the study published in the medical journal Vaccine on February 12, 2024 link to a copy of the study below.


K. Faksova

Department of Epidemiology Research,
Statens Serum Institut,
Copenhagen, Denmark

Corresponding author at: Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, Copenhagen S 2300, Denmark.

Write and ask.